The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry and the focus for development of protective antibodies and vaccines. Structural studies show exposed sites on the spike trimer that might be targeted by antibodies with cross-species specificity. Here we isolated two human monoclonal antibodies from immunized humanized mice that display a remarkable cross-reactivity against distinct spike proteins of betacoronaviruses including SARS-CoV, SARS-CoV-2, MERS-CoV and the endemic human coronavirus HCoV-OC43. Both cross-reactive antibodies target the stem helix in the spike S2 fusion subunit which, in the prefusion conformation of trimeric spike, forms a surface exposed membrane-proximal helical bu...
: Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants diminishes the ...
Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic ...
The protective human antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-...
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry...
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry...
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry...
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry...
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry...
After virus infection, or upon vaccination our immune system develops a repertoire of functionally d...
After virus infection, or upon vaccination our immune system develops a repertoire of functionally d...
Summary: Current coronavirus (CoV) vaccines primarily target immunodominant epitopes in the S1 subun...
The spillovers of betacoronaviruses in humans and the emergence of severe acute respiratory syndrome...
Current coronavirus vaccines primarily target immunodominant epitopes in the S1 subunit, which are p...
Current coronavirus vaccines primarily target immunodominant epitopes in the S1 subunit, which are p...
Broadly neutralizing antibodies (bnAbs) to coronaviruses (CoVs) are valuable in their own right as p...
: Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants diminishes the ...
Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic ...
The protective human antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-...
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry...
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry...
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry...
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry...
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry...
After virus infection, or upon vaccination our immune system develops a repertoire of functionally d...
After virus infection, or upon vaccination our immune system develops a repertoire of functionally d...
Summary: Current coronavirus (CoV) vaccines primarily target immunodominant epitopes in the S1 subun...
The spillovers of betacoronaviruses in humans and the emergence of severe acute respiratory syndrome...
Current coronavirus vaccines primarily target immunodominant epitopes in the S1 subunit, which are p...
Current coronavirus vaccines primarily target immunodominant epitopes in the S1 subunit, which are p...
Broadly neutralizing antibodies (bnAbs) to coronaviruses (CoVs) are valuable in their own right as p...
: Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants diminishes the ...
Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic ...
The protective human antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-...